Company news
Zhejiang CONBA Pharmaceutical Co., Ltd. news in 2025
Zhejiang CONBA Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2025, newest first.
Announcement on Election of Chairman, Vice Chairman, and Other Matters
December 30, 2025
Announcement on Propiverine Hydrochloride Inhalation Solution Obtaining Drug Registration Certificate by Subsidiary
December 29, 2025
Announcement on Proposed Shareholding Increase Plan by the Controlling Shareholder Zhejiang Medicine Group through Block Trading
December 22, 2025
Announcement on Resignation Matters of Chairman, Legal Representative and Other Personnel
December 5, 2025
Announcement on Notifying Creditors of Registered Capital Reduction
November 28, 2025
Announcement on Implementation of Independent Exercise in the 2nd Exercise Period of Stock Options Initially Granted in 2022 Stock Option Incentive Plan
November 24, 2025
Announcement on the Completion of Cancellation of Some Stock Options under the 2022 Stock Option Incentive Plan
November 13, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 11, 2025
Announcement on Compliance with Exercise Conditions for the 1st Vesting Period of Stock Options Reserve Granted under 2022 Stock Option Incentive Plan
November 6, 2025
Announcement on Resolutions of the 11th (Extraordinary) Meeting of the 11th Board of Directors
October 28, 2025
Indicative Announcement on Restricted Exercise Period for the First Vesting Period of Stock Options Initially Granted in 2022 Stock Option Incentive Plan
October 17, 2025
Announcement on Voluntary Exercise Results of Stock Option Incentive Plan in Q3 2025 and Share Changes
October 9, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing and Collection of Questions
September 15, 2025
Announcement on Approval for Registration of Ultra-short-term Financing Bonds and Medium-term Notes
September 10, 2025
Announcement on Subsidiary's Obtainment of Drug Registration Certificate for Compound Ipratropium Bromide Solution for Inhalation
September 8, 2025
Announcement on Obtaining Drug Registration Certificate for Linggui Zhugan Decoction Granules
September 3, 2025
Full Text of the Semi-annual Report
August 27, 2025
Announcement on Shareholding Reduction Plan of through Call Auction by Shareholder
August 15, 2025
Indicative Announcement on the Change in Equity of Shareholders Holding More Than 5% and Their Persons Acting in Concert
August 5, 2025
Announcement on Subsidiary's Obtainment of Drug Registration Certificate for Tranexamic Acid Tablets
July 31, 2025
Announcement on Obtaining Drug Registration Certificate for Perindopril Amlodipine Tablets (III)
July 28, 2025
Announcement on Cancelling Implementation Result of Share Repurchase and Share Changes
July 8, 2025
Announcement on Voluntary Exercise Results of Stock Option Incentive Plan in Q2 2025 and Share Changes
July 1, 2025
Announcement on Implementation of Dividend Distribution for 2024
June 18, 2025
Announcement on Adjusting the Exercise Price of Stock Options in the 2022 Stock Option Incentive Plan
June 13, 2025
Indicative Announcement on Adjustment of Restricted Exercise Period for the First Vesting Period of Stock Options Initially Granted in 2022 Stock Option Incentive Plan
June 11, 2025
Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
June 10, 2025
Announcement on Obtaining Drug Registration Certificate for QingYanHouHanPian
May 27, 2025
Announcement on Cancellation of the Repurchased Shares, Reduction of Registered Capital and Notification to Creditors
May 23, 2025